Advanced search
Publication Cover
Pain Management Volume 12, 2022 - Issue 6
Submit an article Journal homepage
913
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Postsurgical neuropathic pain: lidocaine 700 mg medicated plaster or oral treatments in clinical practice

Michael A Überall1 Institute of Neurological Sciences, Nürnberg, 90411, GermanyORCID Iconhttps://orcid.org/0000-0001-7165-9492View further author information
ORCID Icon,
Irmgard Bösl2 Grünenthal GmbH, Aachen, 52078, GermanyView further author information
,
Els Hollanders2 Grünenthal GmbH, Aachen, 52078, GermanyView further author information
,
Ingo Sabatschus2 Grünenthal GmbH, Aachen, 52078, GermanyORCID Iconhttps://orcid.org/0000-0002-5317-7171View further author information
ORCID Icon &
Mariëlle Eerdekens2 Grünenthal GmbH, Aachen, 52078, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6198-4806View further author information
ORCID Icon
Pages 725-735 | Received 04 May 2022, Accepted 01 Jun 2022, Published online: 17 Jun 2022

Figures & data

Table 1. Baseline characteristics of all patients with postsurgical neuropathic pain.

Figure 1. Oral recommended first-line medications documented for the treatment of postsurgical neuropathic pain in the OM group after switch from previous medication (n = 531).

OM: Oral first-line medication; SSNRI: Selective serotonin-norepinephrine reuptake inhibitor.

Figure 1. Oral recommended first-line medications documented for the treatment of postsurgical neuropathic pain in the OM group after switch from previous medication (n = 531).OM: Oral first-line medication; SSNRI: Selective serotonin-norepinephrine reuptake inhibitor.
Figure 2. Change in concomitant medication and in rescue medication over the 24-week observation period.

Data for nonopioids and mild opioids are not shown.

LMP: Lidocaine 700 mg medicated plaster; OM: Oral medication.

Figure 2. Change in concomitant medication and in rescue medication over the 24-week observation period.Data for nonopioids and mild opioids are not shown.LMP: Lidocaine 700 mg medicated plaster; OM: Oral medication.
Figure 3. Average 24-h pain intensity index.

(A) Change from baseline over the observation period. (B) Improvement versus baseline at end of observation.

PIX: Pain intensity index.

Figure 3. Average 24-h pain intensity index. (A) Change from baseline over the observation period. (B) Improvement versus baseline at end of observation.PIX: Pain intensity index.
Figure 4. Overall quality of life.

Change in physical component score over the observation period.

Figure 4. Overall quality of life.Change in physical component score over the observation period.

Table 2. Outcome of further effectiveness parameters at the end of observation.

Figure 5. Drug-related adverse events over the observation period.
Figure 5. Drug-related adverse events over the observation period.

Table 3. All drug-related adverse events reported in patients receiving lidocaine 700 mg medicated plaster during the observation period (n = 531).

Table 4. Main drug-related adverse events reported in patients receiving oral first-line medication during the observation period (n = 531).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.